


Movement Disorders / Volume 28, Issue 6 / p. 836-839

Brief Report

Pilot study of H₂ therapy in Parkinson's disease: A randomized double-blind placebo-controlled trial

Asako Yoritaka MD, PhD, Masashi Takanashi MD, PhD, Masaaki Hirayama MD, PhD, Toshiki Nakahara MD, PhD, Shigeo Ohta PhD, Nobutaka Hattori MD, PhD 

First published: 11 February 2013

<https://doi.org/10.1002/mds.25375>

Citations: 100

Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.

Abstract

Background

Oxidative stress is involved in the progression of Parkinson's disease (PD). Recent studies have confirmed that molecular hydrogen (H₂) functions as a highly effective antioxidant in cultured cells and animal models. Drinking H₂-dissolved water (H₂-water) reduced oxidative stress and improved Parkinson's features in model animals.

Methods

In this a placebo-controlled, randomized, double-blind, parallel-group clinical pilot study, the authors assessed the efficacy of H₂-water in Japanese patients with levodopa-medicated PD. Participants drank 1,000 mL/day of H₂-water or pseudo water for 48 weeks.

This website stores data such as cookies to enable essential site functionality, as well as marketing, personalization, and analytics. By remaining on this website you indicate your consent. [Privacy Policy](#)

placebo group (n=8) worsened (median, 4.5; mean±standard deviation, 4.1±9.2). Despite the minimal number of patients and the short duration of the trial, the difference was significant ($P<0.05$).

Conclusions

The results indicated that drinking H₂-water was safe and well tolerated, and a significant improvement in total UPDRS scores for patients in the H₂-water group was demonstrated. © 2013 *Movement Disorder Society*

References

- 1 Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD. Increased nigral iron content in postmortem Parkinsonian brain. *Lancet* 1987; **8569**: 1219– 1220.
- 2 Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. *Proc Natl Acad Sci U S A* 1996; **93**: 2696– 2701.
- 3 Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. *Nat Med* 2007; **13**: 688– 694.
- 4 Ohta S. Molecular hydrogen is a novel antioxidant to efficiently reduce oxidative stress with potential for the improvement of mitochondrial diseases. *Biochim Biophys Acta* 2012; **1820**: 586– 594.
- 5 Fujita K, Seike T, Yutsudo N, et al. Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease [serial online]. *PLoS One* 2009; **30**: e7247.

This website stores data such as cookies to enable essential site functionality, as well as marketing, personalization, and analytics. By remaining on this website you indicate your consent. [Privacy Policy](#)

7 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry* 1992; **55**: 181– 184.

8 Nagata K, Nakashima-Kamimura N, Mikami T, Ohsawa I, Ohta S. Consumption of molecular hydrogen prevents the stress-induced impairments in hippocampus-dependent learning tasks during chronic physical restraint in mice. *Neuropsychopharmacology* 2009; **34**: 501– 508.

9 Shimouchi A, Nose K, Shirai M, Kondo T. Estimation of molecular hydrogen consumption in the human whole body after the ingestion of hydrogen-rich water. *Adv Exp Med Biol* 2012; **737**: 245– 250.

10 Ohno K, Ito M, Ichihara M, Ito M. Molecular hydrogen as an emerging therapeutic medical gas for neurodegenerative and other disease [serial online]. *Oxid Med Cell Longev* 2012; **2012**: 353152.

11 Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson's disease. *Mov Disord* 2011; **26**: S2– S41.

Citing Literature



[Download PDF](#)



International Parkinson and
Movement Disorder Society

This website stores data such as cookies to enable essential site functionality, as well as marketing, personalization, and analytics. By remaining on this website you indicate your consent. [Privacy Policy](#)

RESOURCES 

Julie Nash
Managing Editor
mdjedoffice@gmail.com

EDITOR-IN-CHIEF

A. Jon Stoessl, CM, MD, FRCPC, FCAHS
University of British Columbia
Vancouver, British Columbia, Canada

© 1998-2023 International Parkinson and Movement Disorder Society. All Rights Reserved.

About Wiley Online Library

[Privacy Policy](#)[Terms of Use](#)[About Cookies](#)[Manage Cookies](#)[Accessibility](#)[Wiley Research DE&I Statement and Publishing Policies](#)[Help & Support](#)[Contact Us](#)[Training and Support](#)[DMCA & Reporting Piracy](#)[Opportunities](#)[Subscription Agents](#)[Advertisers & Corporate Partners](#)[Connect with Wiley](#)[The Wiley Network](#)[Wiley Press Room](#)

This website stores data such as cookies to enable essential site functionality, as well as marketing, personalization, and analytics. By remaining on this website you indicate your consent. [Privacy Policy](#)

This website stores data such as cookies to enable essential site functionality, as well as marketing, personalization, and analytics. By remaining on this website you indicate your consent. [Privacy Policy](#)